Cargando…

The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients

OBJECTIVE: Thyroid hormones have been implicated to play a role in cardiovascular disease, along with studies linking thyroid hormone to kidney function. The aim of this study is to investigate whether kidney function modifies the association of subclinical thyroid dysfunction and the risk of cardio...

Descripción completa

Detalles Bibliográficos
Autores principales: Zijlstra, L E, van Velzen, D M, Simsek, S, Mooijaart, S P, van Buren, M, Stott, D J, Ford, I, Jukema, J W, Trompet, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993270/
https://www.ncbi.nlm.nih.gov/pubmed/31846431
http://dx.doi.org/10.1530/EC-19-0502
_version_ 1783492995680567296
author Zijlstra, L E
van Velzen, D M
Simsek, S
Mooijaart, S P
van Buren, M
Stott, D J
Ford, I
Jukema, J W
Trompet, S
author_facet Zijlstra, L E
van Velzen, D M
Simsek, S
Mooijaart, S P
van Buren, M
Stott, D J
Ford, I
Jukema, J W
Trompet, S
author_sort Zijlstra, L E
collection PubMed
description OBJECTIVE: Thyroid hormones have been implicated to play a role in cardiovascular disease, along with studies linking thyroid hormone to kidney function. The aim of this study is to investigate whether kidney function modifies the association of subclinical thyroid dysfunction and the risk of cardiovascular outcomes. METHODS: In total, 5804 patients were included in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). For the current analysis, 426 were excluded because of overt thyroid disease at baseline or 6 months, 266 because of inconsistent thyroid function at baseline and 6 months, 294 because of medication use that could influence thyroid function, and 16 because of missing kidney or thyroid values. Participants with normal fT4 were classified, based on TSH both at inclusion and 6 months, into three groups: subclinical hypothyroidism (TSH >4.5 mIU/L); euthyroidism (TSH = 0.45–4.5 mIU/L); and subclinical hyperthyroidism (TSH <0.45 mIU/L). Strata of kidney function were made based on estimated glomerular filtration rate into three clinically relevant groups: <45, 45–60, and >60 mL/min/1.73 m(2). The primary endpoint consists of death from coronary heart disease, non-fatal myocardial infarction and (non)fatal stroke. RESULTS: Mean age was 75.3 years, and 49.0% patients were male. Mean follow-up was 3.2 years. Of all participants, 109 subjects (2.2%) had subclinical hypothyroidism, 4573 (94.0%) had euthyroidism, and 182 (3.7%) subclinical hyperthyroidism. For patients with subclinical hypothyroidism, euthyroidism, and subclinical hyperthyroidism, primary outcome occurred in 9 (8.3%), 712 (15.6%), and 23 (12.6%) patients, respectively. No statistically significant relationship was found between subclinical thyroid dysfunction and primary endpoint with adjusted hazard ratios of 0.51 (0.24–1.07) comparing subclinical hyperthyroidism and 0.90 (0.58–1.39) comparing subclinical hypothyroidism with euthyroidism. Neither was this relationship present in any of the strata of kidney function, nor did kidney function interact with subclinical thyroid dysfunction in the association with primary endpoint (P interaction = 0.602 for subclinical hyperthyroidism and 0.388 for subclinical hypothyroidism). CONCLUSIONS: In this secondary analysis from PROSPER, we found no evidence that the potential association between thyroid hormones and cardiovascular disease is modified by kidney function in older patients with subclinical thyroid dysfunction.
format Online
Article
Text
id pubmed-6993270
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-69932702020-02-03 The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients Zijlstra, L E van Velzen, D M Simsek, S Mooijaart, S P van Buren, M Stott, D J Ford, I Jukema, J W Trompet, S Endocr Connect Research OBJECTIVE: Thyroid hormones have been implicated to play a role in cardiovascular disease, along with studies linking thyroid hormone to kidney function. The aim of this study is to investigate whether kidney function modifies the association of subclinical thyroid dysfunction and the risk of cardiovascular outcomes. METHODS: In total, 5804 patients were included in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). For the current analysis, 426 were excluded because of overt thyroid disease at baseline or 6 months, 266 because of inconsistent thyroid function at baseline and 6 months, 294 because of medication use that could influence thyroid function, and 16 because of missing kidney or thyroid values. Participants with normal fT4 were classified, based on TSH both at inclusion and 6 months, into three groups: subclinical hypothyroidism (TSH >4.5 mIU/L); euthyroidism (TSH = 0.45–4.5 mIU/L); and subclinical hyperthyroidism (TSH <0.45 mIU/L). Strata of kidney function were made based on estimated glomerular filtration rate into three clinically relevant groups: <45, 45–60, and >60 mL/min/1.73 m(2). The primary endpoint consists of death from coronary heart disease, non-fatal myocardial infarction and (non)fatal stroke. RESULTS: Mean age was 75.3 years, and 49.0% patients were male. Mean follow-up was 3.2 years. Of all participants, 109 subjects (2.2%) had subclinical hypothyroidism, 4573 (94.0%) had euthyroidism, and 182 (3.7%) subclinical hyperthyroidism. For patients with subclinical hypothyroidism, euthyroidism, and subclinical hyperthyroidism, primary outcome occurred in 9 (8.3%), 712 (15.6%), and 23 (12.6%) patients, respectively. No statistically significant relationship was found between subclinical thyroid dysfunction and primary endpoint with adjusted hazard ratios of 0.51 (0.24–1.07) comparing subclinical hyperthyroidism and 0.90 (0.58–1.39) comparing subclinical hypothyroidism with euthyroidism. Neither was this relationship present in any of the strata of kidney function, nor did kidney function interact with subclinical thyroid dysfunction in the association with primary endpoint (P interaction = 0.602 for subclinical hyperthyroidism and 0.388 for subclinical hypothyroidism). CONCLUSIONS: In this secondary analysis from PROSPER, we found no evidence that the potential association between thyroid hormones and cardiovascular disease is modified by kidney function in older patients with subclinical thyroid dysfunction. Bioscientifica Ltd 2019-12-17 /pmc/articles/PMC6993270/ /pubmed/31846431 http://dx.doi.org/10.1530/EC-19-0502 Text en © 2020 The authors http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Research
Zijlstra, L E
van Velzen, D M
Simsek, S
Mooijaart, S P
van Buren, M
Stott, D J
Ford, I
Jukema, J W
Trompet, S
The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients
title The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients
title_full The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients
title_fullStr The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients
title_full_unstemmed The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients
title_short The kidney, subclinical thyroid disease and cardiovascular outcomes in older patients
title_sort kidney, subclinical thyroid disease and cardiovascular outcomes in older patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993270/
https://www.ncbi.nlm.nih.gov/pubmed/31846431
http://dx.doi.org/10.1530/EC-19-0502
work_keys_str_mv AT zijlstrale thekidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients
AT vanvelzendm thekidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients
AT simseks thekidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients
AT mooijaartsp thekidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients
AT vanburenm thekidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients
AT stottdj thekidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients
AT fordi thekidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients
AT jukemajw thekidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients
AT trompets thekidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients
AT zijlstrale kidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients
AT vanvelzendm kidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients
AT simseks kidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients
AT mooijaartsp kidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients
AT vanburenm kidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients
AT stottdj kidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients
AT fordi kidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients
AT jukemajw kidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients
AT trompets kidneysubclinicalthyroiddiseaseandcardiovascularoutcomesinolderpatients